topic

405 Next-generation pan-cancer immunotherapy with patient-derived APC
Zhen Bian, Lei Shi, Jane Zen, Harry Stylli, Yuan Liu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A454; DOI: 10.1136/jitc-2023-SITC2023.0405
406 Reprogramming the glioma immunosuppressive tumor microenvironment with engineered myeloid cells that release IL-2 to delay malignant progression
Alessandro Canella, Matthew Nazzaro, Claire Schmitt, Abigail Haffey, Giovanni Nigita, Gregory K Behbehani, Prajwal Rajappa

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A455; DOI: 10.1136/jitc-2023-SITC2023.0406
407 Tumor associated mitochondria antigens (TAMAs) as target for cancer vaccine: from the mechanisms to the clinical validation
Francesca Costabile, Stefano Pierini, Renzo Perales-Linares, Adham Bear, Cameron Koch, Linette Gerald, Beatriz Carreno, Michael Lotze, Costantinos Koumenis, Andrea Facciabene

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A456; DOI: 10.1136/jitc-2023-SITC2023.0407
408 PK/PD biomarker analysis to assess tumor-specific enrichment and payload delivery of ACTM-838, a microbial-based immunotherapy
Kyle Cron, Ping Fang, Oanh Pham, Julie Janes, John Brandenburg, Sara Tribble, Emily Miyashita-Lin, Hailey He, Omkar Joshi, Christopher Thanos, Chan Whiting, Akshata R Udyavar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A457; DOI: 10.1136/jitc-2023-SITC2023.0408
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics
Jasmine N Edelstein, Tyler F Hill, Michael D Leiken, Katherine M Molloy, Glory Adekanye, Caroline Bullock, Adam S Lazorchak, Ken-Edwin Aryee, David J Rawlings, Richard G James, Richard A Morgan, Sean P Arlauckas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A458; DOI: 10.1136/jitc-2023-SITC2023.0409
410 Racial and ethnic differences in blood T-cell, B-cell, and NK-cell concentrations may impact sourcing of starting materials for engineered immune cell therapeutic products
Arianna Favela, Ethan Deitcher, Kirk Trisler, Steven R Deitcher

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A459; DOI: 10.1136/jitc-2023-SITC2023.0410
411 Programming immunogenicity of bacterial cancer therapy with biosensor-driven encapsulation systems
Jaeseung Hahn, Tetsuhiro Harimoto, Yu-Yu Chen, Filippo Liguori, Tal Danino

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A460-A461; DOI: 10.1136/jitc-2023-SITC2023.0411
413 IBR403, a novel small molecule, enables scalable manufacturing of HSC-derived natural killer cells for cancer immunotherapy
Shyama Chaganti, Bauer LeSavage, Stefanie Mauer, James Liu, Peretz Partensky, Jesse Cotari, Nina Horowitz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A462; DOI: 10.1136/jitc-2023-SITC2023.0413
414 Efficacy and immunogenicity of induced pluripotent stem cell (iPSC) vaccine is independent of iPSC viability in a prophylactic mouse model of breast cancer
Matthias Hundt, Sahil Inamdar, Hui Huang, Hong Dai, Carlos A Obejero-Paz, Pratima Kundu, Ivan Hernandez, Nigel G Kooreman, Stephen D Wolpe, Lynne A Bui

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A463; DOI: 10.1136/jitc-2023-SITC2023.0414
415 Both allogeneic and syngeneic induced pluripotent stem cell (iPSC) vaccines decrease tumor growth and improve survival in a prophylactic mouse model of breast cancer
Sahil Inamdar, Carlos A Obejero-Paz, Pratima Kundu, Skylar R Foust, Ivan Hernandez, Nigel G Kooreman, Stephen D Wolpe, Lynne A Bui, Matthias Hundt

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A464; DOI: 10.1136/jitc-2023-SITC2023.0415

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages